Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19

Thomas Robert (1) , Guillaume Lano (2) , Noemie Resseguier , Mickael Bobot (2) , Dammar Bouchouareb , Stephane Burtey (2) , Xavier De Lamballerie (3) , Jean Dhorne , Bertrand Dussol , Ariane Duval , Julien Faraut , Toscane Fourie , Philippe Giaime , Mourad Hallah , Dominique Jaubert , Oceane Jehel , Tristan Legris , Stephane Liotatis , Valerie Moal , Laetitia Ninove (3) , Nathalie Pedinielli , Marion Pelletier , Manon Romeu-Giannoli , Mariela Saba , Marion Sallee , Laurent Samson , Adriana Saveanu , Violaine Scarfogliere , Pascale Sebahoun , Romain Vial , Clarissa von Kotze (2) , Philippe Brunet (2) , Gaetan Lebrun , Stanislas Bataille (2) , Noemie Jourde-Chiche (2)

1 MMG - Marseille medical genetics - Centre de génétique médicale de Marseille
2 C2VN - Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research
3 UVE - Unité des Virus Emergents

Hemodialysis (HD) patients are at risk for severe COVID-19 and cannot comply with social distancing. SARS-COV2 seroprevalence in French patients and caregivers after the first wave of COVID-19 is unknown. SeroCOVIDial is a prospective study conducted between June and December 2020. SARS-COV2 seroprevalence was evaluated by a rapid serological test (BIOSYNEX) in HD patients and caregivers, and the presence or not of anti-SARS-COV2 neutralizing or non-neutralizing antibodies in patients was also determined by ELISA and seroneutralization. In June 2020, 451 HD patients and 238 caregivers were included. Overall SARS-COV2 seroprevalence was 8.4% (patients) and 6.7% (caregivers), and was 87.1% (patients) and 90.0% (caregivers) in participants with a previously documented SARS-COV2 infection. Overall seroprevalence reached 13.8% (patients) and 12.6% (caregivers) following the second epidemic wave. During the follow-up, 38 (8.4%) patients died (9 of COVID-19). Among the 44 (10.6%) patients who became infected, only two were seropositive at M0. The levels of anti-SARS-COV2 antibodies decreased over time in patients and caregivers. The BIOSYNEX test showed 82.9% sensitivity and 97.7% specificity. Prevalence of anti-SARS-COV2 antibodies was low in HD patients and caregivers after the first epidemic wave but rose after the second wave. A rapid serological test showed good performances and could be useful for future monitoring of anti-SARS-COV2 antibodies.

Domaines: Génétique

Thomas Robert, Guillaume Lano, Noemie Resseguier, Mickael Bobot, Dammar Bouchouareb, et al.. Presence of specific SARS-COV2 antibodies in hemodialysis patients and their caregivers after the first wave of COVID-19. SCIENTIFIC REPORTS, 2022, 12 (1), pp.11972. ⟨10.1038/s41598-022-15913-0⟩. ⟨hal-03780351⟩